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Abstract
Background: Candida species are the most frequently found fungal pathogens causing nosocomial disease in a
hospital setting. Such species must be correctly identified to ensure that appropriate control measures are taken and
that suitable treatment is given for each species. Candida albicans is causing most fungal disease burden worldwide;
the challenge lies in differentiating it from emerging atypical, minor and related species such as Candida dubliniensis
and Candida africana. The purpose of this study was to compare identification based on MALDI-TOF MS to standard
identification systems using a set of nosocomial isolates.
Methods: Eleven nosocomial samples were collected from 6 third-level hospitals in Bogotá, Colombia. All the samples
were identified by combining MALDI-TOF MS with morphological characters, carbohydrate assimilation and molecular
markers (D1/D2 and HWP1).
Results: The present work describes the first collection of atypical Colombian Candida clinical isolates; these were
identified as Candida albicans/Candida africana by their MALDI-TOF MS profile. Phenotypical characteristics showed that
they were unable to produce chlamydospores, assimilate trehalose, glucosamine, N- acetyl-glucosamine and barely grew
at 42 °C, as would be expected for Candida africana. The molecular identification of the D1/D2 region of large subunit
ribosomal RNA and HWP1 hyphal cell wall protein 1 sequences from these isolates was consistent with those for Candida
albicans. The mass spectra obtained by MALDI-TOF MS were analysed by multi-dimensional scaling (MDS) and cluster
analysis, differences being revealed between Candida albicans, Candida africana, Candida dubliniensis reference spectra
and two clinical isolate groups which clustered according to the clinical setting, one of them being clearly related to C.
albicans.
Conclusion: This study highlights the importance of using MALDI-TOF MS in combination with morphology, substrate
assimilation and molecular markers for characterising Candida albicans-related and atypical C. albicans species, thereby
overcoming conventional identification methods. This is the first report of hospital-obtained isolates of this type in
Colombia; the approach followed might be useful for gathering knowledge regarding local epidemiology which could, in
turn, have an impact on clinical management. The findings highlight the complexity of distinguishing between typical
and atypical Candida albicans isolates in hospitals.
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Background
Candida albicans is the pathogenic fungus most com-
monly found in the general population; its ease of trans-
mission in hospitals causes high comorbidity rates [1, 2].
This species causes mucosal infections, mainly oropha-
ryngeal candidiasis (OPC) and vulvovaginal candidiasis
(VVC); however, the relevant nosocomial presentation is
related to candidaemia and invasive candidiasis which is
associated with high mortality rates (~49 %) in an ICU
[3]. C. albicans minor and related species have been
identified worldwide and, interestingly, types may be as-
sociated with particular patterns of clinical presentation
[4–8]. C. dubliniensis was described in 1995 as being the
first C. albicans-related species, initially in patients hav-
ing a background of HIV and infection in the oral cavity
[4, 9]. C. africana was described in 2001 as being an-
other related species associated with vaginal infection;
one case of bloodstream infection has been reported in
Chile [4, 5, 7].
The timely identification of a microorganism is one of
the challenges for clinical practice and controlling
hospital-acquired infection, thereby facilitating decision-
making for therapeutic prescription and epidemiological
surveillance. The identification methods currently avail-
able in hospitals may not be suitable for the precise
identification of C. albicans-related species. A lack of
chlamydospore formation, an inability to assimilate tre-
halose or amino sugars and poor growth at 42 °C are the
most useful traits for distinguishing C. africana from C.
albicans and C. dubliniensis [5, 6, 10, 11].
Molecular markers such as large-subunit rRNA D1/D2
domain and hyphal cell wall protein 1 (HWP1) DNA se-
quence are also useful tools for species identification [6,
10, 12]. Matrix-assisted laser desorption/ionisation time
of flight mass spectrometry (MALDI-TOF MS) currently
provides an accurate, rapid and relatively inexpensive ap-
proach to yeast typing, having ~97.6 % accuracy in iden-
tifying Candida species [13–18].
Nowadays, there are new challenges in detection-related
medical mycology, identification and classification of
pathogenic fungi. Regarding C. albicans, there is concern
due to the identification of minor species such as C. dubli-
niensis and C. albicans-related ones (such as C. africana
and C. stellatoidea) which have been grouped within the
C. albicans complex [19]. These minor and bio-variant
species cause disease at a specific anatomical location or
site depending on the infecting species; precise identifica-
tion by conventional methods has proven difficult to date
[15, 19] and this situation could lead to overestimating the
epidemiological prevalence of C. albicans. Misdiagnosis
may mask such atypical organisms’ clinical implications
related to their pathology and virulence [19, 20].
Candida africana seems to be a new player in the
clinical picture of infectious diseases. Most reported
infection attributed to this species is located in the geni-
tal tract; however, studies on this matter have been lim-
ited to date. Despite C. africana having been considered
less pathogenic than C. albicans due to its anatomical
localisation, the pathogenic consequences when infec-
tions occur at other sites of the host require further
study [19, 21].
Taxonomic discussion concerning this new variant in-
cludes the fact that studies have demonstrated that C.
albicans and C. africana are very close, as assessed by
phylogenetic position based on studies of sequences
from the D1/D2 region of their 28S ribosomal RNA
genes. The same situation has occurred with internal
transcribed spacer (ITS) sequence regions having 99.3–
99.8 % identity, this being almost identical to C. albicans
intraspecies values (99.8–100 %). Whether C. africana
should be considered a new species or biovar is still
open to discussion; however, some authors have consid-
ered that there are specific molecular markers such as
the HWP1 gene and additional different phenotypic
traits such as carbon assimilation and no chlamydospore
formation can establish a real difference from its closest
relative C. albicans [22].
Our research group has thus been interested in
evaluating how combining MALDI-TOF MS with
morphology, substrate assimilation and molecular
markers can be used to characterise these atypical C.
albicans isolates from clinical settings. This initiative
began after peculiar phenotypical traits were found in
some clinical isolates taken from patients from six
local hospitals diagnosed as having nosocomial infec-
tion by C. albicans (i.e., low cellular adhesion, smaller
yeast size and slower growth).
Methods
Ethics statement
Committees from the following institutions approved
this study: Universidad del Rosario’s ethics committee,
covering its associated institutions (Hospital de Kennedy,
Hospital Simón Bolívar, Hospital El Tunal, Hospital la
Samaritana and Clínica de Occidente) and the Hospital
San Ignacio’s ethics committee. Samples were taken as
part of standard care and were irreversibly anonymised;
following ethical guidelines, no patient consent was thus
required for research purposes, taking into account that
this is no longer considered personal data.
Strains and isolates
Isolates were collected from two sources; 40 nosocomial
isolates were obtained from 10 third-level hospitals and
then identified by MALDI-TOF MS in a first batch. The
second phase involved 240 isolates processed by MALDI-
TOF MS from hospital samples from the San Ignacio
HUSI teaching hospital in Bogotá, Colombia. Table 1 gives
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such isolates’ clinical characteristics, referring to the origin
of the samples and relevant clinical data.
The nosocomial isolates reported here will be deposited
at the Belgian Coordinated Collections of Micro-organisms
(BCCM/MUCL) once national and international regula-
tions regarding biological material transport have been
met.
The C. albicans SC5314 clinical reference strain, C.
albicans ATCC 90028, C. africana ATCC 2669 and C.
dubliniensis ATCC MYA-646 reference strains were
tested in conventional identification assays as controls.
The Candida glabrata ATCC 2001 reference strain was
used as negative control in chlamydospore formation
assays.
Culture medium
Each isolate was cultured using identical conditions.
The samples were inoculated into Sabouraud agar
(Difco, St Louis, Mo) for 24–48 h at 30, 37, 42 and
45 °C. Identity was confirmed by conventional identi-
fication methods, such as germ tube induction at 37 °C,
microscopic morphology and chlamydospore formation in
corn meal agar (Oxoid, Basingstoke, United Kingdom)
[23]. The SC5314 strain was used as positive control for
chlamydospore formation and the Candida glabrata
ATCC 2001 strain as negative control. Photographs were
taken with an optical light microscope (Leica icc50HD)
at 40×.
Samples were also plated on CHROMagar (Becton
Dickson, Meylan, France) to verify the clinical isolates’
chromogenic presentation, read after 48 h incubation,
according to the manufacturer’s recommendations. The
carbohydrate assimilation pattern was evaluated in stan-
dardised serial assays on yeast nitrogen base (YNB) agar,
containing trehalose, glucosamine and then sucrose as sole
carbon source (5 g/L). The amount of yeast inoculated into
the medium was 103 CFU; this was read after 2 and 5 days
incubation at 30 °C [5].
Isolate identification using API 20C AUX
Fresh cells were collected after culturing in Sabouraud
medium for 48 h at 30 °C; an API 20 C AUX (bioMér-
iux, France) kit was then used, following the manufac-
turer’s recommendations. Growth in each cupule was
visually inspected after 48 h. The codes so obtained were
analysed using apiweb software (bioMériux, France).
Amplifying and sequencing molecular markers
The D1/D2 region of the rRNA gene complex 28 subunit
was amplified following international guidelines for the
molecular identification of fungi for Candida identifica-
tion [10, 12]. The hyphal cell wall protein 1 (HWP1) gene
[6] was also used. Genomic DNA was extracted from iso-
lated colonies grown in Sabouraud dextrose agar (Becton
Dickinson and Co.) using a QIAamp DNA mini kit (QIA-
GEN, Germantown, MD), following the manufacturer’s
recommendations. The molecular markers were amplified
using the primers and protocols previously described for
the D1/D2 region [12] and the HWP1 gene [6].
The amplified products from the D1/D2 region
(~600 bp) were sent to Macrogen (Maryland, USA) for
Sanger bidirectional sequencing. Sequencher 5.0 soft-
ware (Gene Code Corporation) was used for editing and
aligning the sequences. A search was then made in the
following databases for each sequence to establish simi-
larity with known strains: the NCBI databases (BLAST)
(National Center for Biotechnology Information, Wash-
ington, DC), CBS-KNAW (Fungal Biodiversity Centre)
and Mycobank database (International Mycological
Association).
Typing by HWP1 gene was based on the amplified
products’ difference in size: ~ 700 bp for C. africana,
Table 1 Clinical information regarding the isolates studied
Isolate Patient gender Age (in years) Source AF treatment Clinical outcome Clinical setting Locality
CO_R6 F 55 Urine None Dead ICU Kennedy
CO_R41 M 1 month Blood Amphotericin B Alive ICU Usaquen
CO_R111 M 18 Urine Fluconazole Alive ICU Tunjuelito
CO_R282 F 70 Urine None Dead Room San Cristobal
CO_R425 M 70 Urine None Dead ICU Kennedy
CO_B41 M 44 BAL Fluconazole Alive Room Chapinero
CO_B44 F 26 Vaginal swab N.D N.D N.D. Chapinero
CO_B69 F 68 Faeces None Alive Room Chapinero
CO_B60 M 94 Urine None Alive Room Chapinero
CO_B77 M 18 BAL None Alive Room Chapinero
CO_B80 F 73 BAL Voriconazole, caspofungin,
amphotericin B
Dead Room Chapinero
BAL bronchoalveolar lavage, N.D No data
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~ 941 bp for C. albicans and ~ 569 bp for C. dubli-
niensis [6]. The assays were done in triplicate; ampli-
fication product size was assessed on agarose gels.
MALDI-TOF MS
The clinical isolates were cultured in Sabouraud agar for
24–48 h at 30 °C. MALDI-TOF MS was used for identifi-
cation, using the protein extraction in formic acid/ethanol
method, according to the Bruker Daltonics’ protocol with
minor modifications as reported by Cendejas-Bueno et al.,
in 2012 [24]. The identification spectrum was produced
from 240 laser shots in duplicate and compared to the
equipment’s (Bruker) mass spectrum library. Twenty mea-
surements were made for each clinical isolate. The
MALDI-TOF MS results were then compared and a score
was obtained according to the manufacturer’s technical
specifications as follows: correct genus and species identi-
fication (≥2.0), secure genus identification (1.7–2.0) and
no reliable identification (<1.7).
MS identification during measurements was visualised
by Bruker flex analysis software and MALDI Biotyper
RTC [24]. The original, commercially-available Bruker
database, BDAL, is regularly updated by the manufac-
turer. This research was carried out with a BDAL library
containing 4110 main spectra (MSPs) created between
2007 and 2012.
Maldi spectra analysis
Peak readings having less than 5 % relative intensity and
signal/noise less than 3 were eliminated. The spectra ob-
tained from each sample (isolates and reference strains)
were combined, resulting in 15 spectra (11 from the
clinical isolates, two from C. albicans (strains 90028, and
SC5314), one from C. africana (strain ATCC 2699) and
one from C. dubliniensis (strain ATCC MYA-646).
Data binning for each spectrum reduced the effects of
minor observation errors, using 10 m/z as bin interval
(ranging from 2000 to 15,380). The presence of a peak
in a bin was scored as 1, its absence as 0. Distance
matrices were estimated on the resulting binary matrix
(15 × 559) using absolute Pearson and Euclidian mea-
sures; a cluster analysis was then performed using
UPGMA and complete methods. Unbiased bootstrap
values were used to support the obtained trees (1000
replicas), all using the R 3.1.3 pvclust package [25–27].
Metric multi-dimensional scaling (MDS) was also per-
formed on each distance matrix, using the R 3.1.3 stats
package [26].
Results
Clinical features characterising the collected samples
The samples were collected in six third-level hospitals in
Bogotá, Colombia. Samples labelled CO_B were isolated
from clinical settings involving one teaching hospital
(San Ignacio); those labelled CO_R came from 5 third-
level hospitals, most of them (4/5) being isolated from
intensive care units (ICU). The clinical information re-
lated to the samples revealed that only one of them in-
volved vaginal flow; the remainder came from urine,
bronchoalveolar lavage or blood. There were no signifi-
cant differences regarding the 11 patients’ gender and
half of them were more than 60 years-old. Four of them
had received antifungal treatment associated with a diag-
nosis of Candida infection. Table 1 shows that patients
received one or several of the following antifungals in
the doses shown according to each patient’s clinical con-
dition (i.e., urinary tract infection, invasive candidiasis
and candidaemia): fluconazole (400–800 mg/day), vori-
conazole (6/3/mg/kg/day), caspofungin (70/50 mg) or
amphotericin B (0.7–1.0 mg/kg), following international
protocols [28]. Even though this was a small sample, it
should be stated that four out of this group of 11 pa-
tients died and one of these patients died after having
received sequential treatment involving voriconazole,
caspofungin and amphotericin B due to invasive candid-
iasis. All patients had an underlying condition; this was
cancer-related in two cases, one had hepatic failure and
another one suffered chronic renal failure (Table 1).
Identifying atypical Candida albicans by MALDI-TOF MS
Identification consisted of two phases; the first involved
a batch of 40 nosocomial samples (CO_R) from third-
level hospitals in Bogotá which were sent to CBS-
KNAW in Utrecht, the Netherlands. MALDI-TOF MS
output classified 5 of them as C. albicans-C. africana.
These 5 atypical ones were then confirmed in Colombia
in duplicate. Two hundred and forty samples were ob-
tained from the San Ignacio teaching hospital (CO_B)
and processed during a second phase by MALDI-TOF
MS, an extra 6 isolates being classified as C. albicans-C.
africana, following protein extraction in formic acid/
ethanol by the Universidad Javeriana’s Human Proteo-
mics and Mycosis Research Unit (Bogotá, Colombia).
MALDI-TOF MS provided identification with >2.0
scores for all strains tested in duplicate; analysis included
the Candida albicans ATCC 90028, SC5314, C. africana
ATCC 2669 and Candida dubliniensis ATCC MYA-646
reference strains and the clinical isolates (Table 2).
Identifying atypical Candida albicans by morphological,
physiological and molecular markers
As MALDI-TOF MS revealed atypical C. albicans iso-
lates, this led to conventional fungal identification tests.
One such test involved growth in corn meal agar for
verifying chlamydospore formation. Chlamydospore for-
mation was not observed in any of the 11 atypical iso-
lates analysed after a 5-day incubation (Fig. 1b). Three
biological repeats were performed. The SC5314 strain
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Table 2 Clinical isolates’ phenotypical and genotypic characterisation
Candida albicans Candida dubliniensis Atypical Candida albicans




+ + + + + + + + + + + + +
Chlamydospore
production
+ + - - - - - - - - - - -
Pseudohyphae + + +/− +/− +/− +/− +/− +/− +/− +/− +/− +/− +/−
Substrate
assimilation
Trehalose + + - - - - - - - - - - -
Glucosamine + + - - - - - - - - - - -
Sucrose + + + + + + + + + + + + +
API 20C AUX
Code
2576174 6152034 2576034 2576034 2576034 2576034 2576034 2576034 2576034 2576034 2576034 2576034 2576034
Growth
At 30 °C + + + + + + + + + + + + +
At 37 °C + + + + + + + + + + + + +
At 42 °C + - - - - - - - - - - - -
At 45 °C + - - - - - - - - - - - -
Growth in chromogenic medium
CHROMagar Green Green Green Green Green Green Green Green Green Green Green Green Green
Molecular markers
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was used as positive control, revealing chlamydospore
formation (Fig. 1a), and Candida glabrata ATCC 2001
as negative control which showed no chlamydospore for-
mation (Fig. 1c).
Regarding carbon assimilation tests, it was found that
the 11 clinical isolates did not assimilate trehalose or
glucosamine in culture medium; moreover, API 20C
AUX test results showed that these isolates did not as-
similate N-acetyl-glucosamine (like the C. africana ATCC
2669 reference strain). By contrast, the C. albicans SC5314
and ATCC 90028 control strains were able to assimilate
trehalose, glucosamine and N-acetyl-glucosamine. All clin-
ical isolates were unable to grow at 42 °C in growth
temperature tests. Table 2 summarises the main findings,
comparing the clinical C. albicans reference strain SC5314
and C. dubliniensis ATCC MYA-646 (as a related strain) to
atypical isolates.
Concerning molecular markers, D1/D2 sequences from
the 11 isolates had ≥99 % sequence identity with C. albi-
cans (Table 2). Regarding the HWP1 gene amplification,
all clinical isolates had the ~940 bp band characteristic of
C. albicans, whilst the C. africana ATCC 2669 had the ex-
pected ~ 700 bp amplicon and C. dubliniensis control
strain ATCC MYA-646 displayed the expected ~569 bp
amplicon.
Cluster analysis and metric multidimensional scaling (MDS)
Cluster analysis (Fig. 2a) and MDS (Fig. 2b), regard-
less of the clustering method and distance used,
showed four well supported groups. C. dubliniensis
(green) reference strain was clustered as a differenti-
ated element as well as C. africana (purple) reference
strain. The clinical isolates coded CO_B (black) from
the San Ignacio hospital were associated with the C.
albicans strains. The CO_R isolates (red), collected
from five third-level hospitals different to San Ignacio,
were grouped in an independent group, but related to
the CO_B-C. albicans group.
Discussion
This study highlights the usefulness of combining molecu-
lar and phenotypical traits for identifying Candida noso-
comial isolates. MALDI-TOF MS was used as the first
screening method, reporting the 11 clinical isolates as C.
albicans / C. africana. This technique has been validated
as a methodology which improves the diagnosis of fungal
infection, having 98.5 % correct identification for C. albi-
cans when the protein extraction protocol is followed by
identification involving spectrometry [13, 29].
Clinical isolates were identified differently when mo-
lecular markers were used; all clinical isolates were C.
albicans according to D1/D2 sequencing. However, sev-
eral authors have stated that the small difference in se-
quence (just 1 %) between C. albicans and C. africana
using this molecular marker does not properly differenti-
ate between these two species [7, 30]. The HWP1 gene
was thus used to overcome this problem as it has been re-
ported as being appropriate for differentiating C. albicans,
C. africana and C. dubliniensis [6]. This assay, when per-
formed according to Romeo et al., 2008 [6], identified our
11 clinical atypical isolates as C. albicans (Table 2). A
similar result has been described in a report of a clinical
case in Italy where the amplification product obtained was
equal in size to that found for the C. albicans reference
strain, but different to that from C. dubliniensis, its
closely-related species, even though other findings using
conventional identification agreed with C. africana typing
[31]. Such findings supported Romeo and Criseo’s notion
that HWP1 is a useful marker; however, additional meth-
odologies are needed for atypical species to differentiate
the species belonging to this complex [16].
A third line of evidence was established using chlamy-
dospore formation as a morphological trait differentiat-
ing C. albicans (+ for chlamydospore formation) from C.
africana (—for chlamydospore formation) (Table 2).
This criterion has been shown to have physiological rele-
vance since chlamydospore-forming species tend to
A B C
20 µm 
Fig. 1 Evaluating chlamydospore production in corn meal agar. a. Candida albicans SC5314 (positive control): chlamydospores were observed
after 5 days incubation (blue arrows). b. CO_R6 clinical isolate: no chlamydospores were observed after the same incubation period. c. Candida
glabrata ATCC 2001 (negative control): no chlamydospores observed. Image captured by Motic BA200 light microscope (40×)
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resist stress conditions [5]. The remaining phenotypical cri-
teria regarding our clinical isolates also agreed with typical
C. africana characteristics, such as an inability to assimilate
trehalose, glucosamine or N-acetyl-glucosamine [5].
According to Tietz et al., [5] these morphological and
physiological characteristics are very important taxo-
nomic criteria which should have led to identifying our
atypical isolates as C. africana morphospecies; by con-
trast, molecular markers would have indicated that these
isolates belonged to C. albicans.
Such findings question the taxonomic position of these
fungi. Some authors consider C. albicans as a species com-
plex consisting of related species, such as C. africana, C.
stellatoidea and minor species such as C. dubliniensis.
Some clinical particularities are always associated with a
species, i.e., vaginal infection regarding C. africana and a
preceding compromise involving HIV and oral localisation
regarding C. dubliniensis, seeming to be more prevalent in
cystic fibrosis patients [9, 19, 32]. C. africana infection has
been described worldwide in Senegal, Madagascar, Nigeria,
Angola, Germany, Italy, the UK, Spain, Saudi Arabia,
India, Japan, the USA, Chile and China [7, 11, 19, 33–37].
The authors of such reports have highlighted the epi-
demiological importance of correlating these species’ pres-
ence with their true impact on human pathology.
The current work has been the first to describe noso-
comial isolates identified as atypical C. albicans as their
morphological and substrate assimilation fit with C. afri-
cana. Concerning the clinical data reported here, only one
isolate came from vaginal infection whilst the remaining
isolates came from urine, blood, faeces or bronchoalveolar
lavage, meaning that the infection spectrum was broader
and was even associated with triggering the death of some
patients (4/11). However, underlying conditions pertaining
to comorbidity have also to be taken into account. The
mortality rate could not be accurately attributed due to
the small sample size, thereby indicating the need for fur-
ther studies involving an active search for cases to better
establish these atypical species’ degree of impact [19].
Several authors have mentioned new challenges arising
from finding cryptic Candida species, as well as the avail-
able methodology for precisely differentiating variants
which do not fit conventional identification parameters
[16]. MALDI-TOF MS is a useful tool for improving fungal
disease diagnosis [29, 38]. MALDI-TOF MS spectra were
directly analysed here as an additional source of informa-
tion, in a similar way to that reported by Qian et al. [25].
Clustering and MDS results revealed well-defined dif-
ferences amongst C. albicans, C. africana and C. dubli-
niensis reference strains and, more interestingly, two
groups of clinical isolates, one formed by CO_B isolates,
clearly related to C. albicans reference strains, and an-
other formed by CO_R samples. Two different forces
modelling clinical isolates’ clustering pattern may thus
A B
Fig. 2 a. Cluster analysis. The dendrogram was calculated using UPGMA on an absolute correlation distance matrix. Weighted bootstrap values
are indicated (>95 is considered well supported). b. Metric multi-dimensional scaling (MDS). The scatter plot shows the 2D projection of the
absolute correlation matrix. Mass signatures of reference spectra (r) from C. albicans (strains ATCC 90028, SC5314, in blue), C. dubliniensis (ATCC
MYA-646 in green) and C. africana (ATCC 2669 in purple). Clinical isolates from San Ignacio hospital: CO_B (in black). Clinical isolates from other
hospitals: CO_R (in red)
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be proposed. Place of origin and an ICU background (re-
lated to prophylactic antifungal therapy) can provide these
pathogens’ local epidemiological setting. CO_R isolates
came from different hospitals, but had a common back-
ground related to critical patients’ conditions; 4 of the 5
were hospitalised in an ICU and 3 of the 5 in this group
died. Previous exposure to fluconazole could be assumed
in these nosocomial isolates, according to ICU protocols
or these patients’ critical condition (Table 1). Otherwise,
the same place of origin was a common characteristic for
CO_B isolates from a clinical setting involving only one
hospital; these isolates came from patients who had not
been in an ICU, so this group of patients did not have a
critical condition related to prophylactic antifungal ther-
apy. Consequently, the grouping observed for the isolates
from both groups might have reflected differential select-
ive drug pressure and origin.
MALDI-TOF MS spectra analysis may improve infor-
mation regarding each hospital’s local epidemiology; this
could be used as an effective tool for infection control
since the information obtained through MALDI spectra
allows building local libraries closely representing the
real nosocomial flora in each hospital [39]. This high-
lights the challenge of establishing preventative control
in emerging resistance to antifungal therapy.
The foregoing identifies one of the key aspects in defin-
ing diagnosis and treatment, namely the need for timely,
accurate methodologies for identifying microorganisms,
thus facilitating decision-making regarding appropriate
treatment and hospital infection control surveillance pro-
grammes. What happens regarding nosocomial flora
would thus be clearly defined when decisions need to be
made regarding epidemiological control and/or studying
outbreaks of disease [2].
Conclusions
Our results have highlighted the need for additional
markers (both phenotypical and molecular) for resolving
clinical isolates’ identity. The usefulness of combining
MALDI-TOF MS with molecular, morphological and
physiological approaches in identifying atypical Candida
albicans isolates has been shown.
The samples analysed here were classified as C. albicans
by the HWP1 molecular marker which is useful in differ-
entiating between C. albicans-related and minor species.
Samples also had characteristics compatible with C. afri-
cana, as assessed by conventional mycology methods,
such as the absence of chlamydospore formation, an in-
ability to assimilate trehalose, glucosamine or N-acetyl-
glucosamine and inability to grow at 42 °C.
Classification based on clinical isolates’ spectra, com-
paring them to reference strain spectra, led to interest-
ing findings regarding the local epidemiology of the
hospitals participating in this study. This highlighted
such statistical strategies’ usefulness as a tool for ap-
proaching problems concerned with nosocomial infection
involving atypical germs. The reference C. albicans-related
and minor species used were also successfully differenti-
ated; moreover CO_B and C. albicans constituted a com-
mon cluster, whilst CO_R constituted a well differentiated
cluster, meaning that it could be a different bio-variant of
Candida, but still related to C. albicans. These isolates
could thus be considered atypical C. albicans.
Evidence has been presented here concerning the im-
portance of a prophylactic antifungal therapy-related
pharmacological background which can be used as a se-
lective force determining the clustering of a specific iso-
late (CO_R) that reflects common practice in ICUs in
the different hospitals sampled. This would agree with
findings by Sydnor et al., (2011) [2] regarding the spe-
cific hospital location of nosocomial flora and a relation-
ship with and maybe a common origin for ICU Candida
isolates in the samples reported here from different
hospitals.
CO_B isolates had a common hospital origin and more
diverse clinical settings, lacking antifungal prophylactic
guidelines. This factor could lead to less stressful condi-
tions for nosocomial isolates and less selective pressure;
the latter has been considered by Maubon et al., (2014)
[40] as being one of the challenges in establishing pre-
ventative control of emerging resistance to antifungal
therapy. These results suggest that more studies should
be carried out to evaluate whether different antifungal
susceptibility exists between these groups.
The clinical and epidemiological aspects of infection
are relevant, since the pathological implications of these
atypical C. albicans isolates require further molecular
and susceptibility studies for understanding their ability
to adapt (this includes phenotypic plasticity) and their
potential for harming a vulnerable host.
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